Stay on the cutting edge of precision oncology by partnering with Guardant Health.
Empowering the biopharmaceutical industry to deliver breakthrough therapeutics for patients with cancer.
01. Purpose Overview
Precision medicine is driving a new era in oncology drug development.
Biopharma companies are at the forefront of introducing novel targeted therapies, redefining the therapeutic management of cancer. These treatments target the specific alterations or biomarkers of a patient, which can significantly extend progression-free survival compared to traditional chemotherapy or immunotherapy.1-7
Accelerate discovery power with Guardant Health.
Guardant Health has pioneered fast, less invasive blood-based testing across the cancer continuum.
This includes comprehensive genomic and epigenomic profiling, minimal residual disease (MRD) detection, and monitoring. These molecular insights support the development of new therapies.
A liquid biopsy has several advantages and can8-11:
- Accelerate patient enrollment in clinical trials, which is a common challenge
- More quickly deliver insights into a patient’s response to treatment compared to standard imaging
- Capture dynamic tumor evolution over time
- Reliably detect tumor heterogeneity at progression
02. Our Solutions
A trusted partner across the drug development journey.
At Guardant Health, our mission is to conquer cancer with data, and together, we can continue to advance precision oncology and reach more patients.
From translational research to clinical development to commercialization, our BioPharma Solutions portfolio is at the cutting edge of products and best-in-class services. Our portfolio is designed to seamlessly meet your needs at each stage of research and development—all while refining focus and accelerating your outcomes.
03. Global Reach
04. Contact Us
References: 1. Shaw AT, Riely GJ, Bang Y-J, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019;30(7):1121-1126. doi:10.1093/annonc/mdz131 2. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41-50. doi:10.1056/NEJMoa1913662 3. Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol. 2019;37(28):2518-2527. doi:10.1200/JCO.19.00934 4. Camidge DR, Dziadziuszko R, Peters S, et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non–small cell lung cancer in the global phase III ALEX study. J Thorac Oncol. 2019;14(7):1233-1243. doi:10.1016/j.jtho.2019.03.007 5. Novartis. Metastatic Non-Small Cell Lung Cancer (NSCLC) With BRAF V600E Mutation. Published June 2023. Accessed October 4, 2023. https://www.hcp.novartis.com/products/tafinlar-mekinist/metastatic-nsclc/efficacy/ 6. Gadgeel S, Rodríguez-Abreu D, Speranza G, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2020;38(14):1505-1517. doi:10.1200/JCO.19.03136 7. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542-2550. doi:10.1056/NEJMoa061884 8. Leighl NB, Page RD, Raymond VM, et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin Cancer Res. 2019;25(15):4691-4700. doi:10.1158/1078-0432.CCR-19-0624 9. Nakamura Y, Taniguchi H, Ikeda M, et al. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med. 2020;26(12):1859-1864. doi:10.1038/s41591-020-1063-5 10. Zhang Q, Luo J, Wu S, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 2020;10(12):1842-1853. doi:10.1158/2159-8290.CD-20-0047 11. Muthamilselvan S, Raghavendran A, Palaniappan A. Stage-differentiated ensemble modeling of DNA methylation landscapes uncovers salient biomarkers and prognostic signatures in colorectal cancer progression. PLoS One. 2022;17(2):e0249151. doi:10.1371/journal.pone.0249151